Clinical Trial Update: Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety study of Infanrix Hexa in infants completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis
• Tetanus

Drugs mentioned

• Infanrix Hexa (DTPa-HBV-IPV/Hib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Poliomyelitis, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2019-01-25